Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06218290 | A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis | PHASE2 | COMPLETED | 106 | — | — | Dec 15, 2023 | May 29, 2024 | Jun 24, 2024 | 7 | United States |
Tolerability of clinically effective doses of OLC as assessed by the incidence of treatment-related AEs leading to study drug discontinuation during the Maintenance Period.
| Arm | Type | Description |
|---|---|---|
| All Patients | EXPERIMENTAL | All patients with chronic kidney disease with hyperphosphatemia |
| Name | Type | Description |
|---|---|---|
| Oxylanthanum Carbonate | DRUG | Phosphate Binder to Reduce Hyperphosphatemia |
Inclusion Criteria: 1. Patient must be ≥18 years of age. 2. Patient must be willing and capable of giving written Informed Consent, adhering to dosing and visit schedules, and meeting all study requirements. 3. Patient must be willing and able to swallow whole tablets. 4. Patient has chronic kidney...